169 related articles for article (PubMed ID: 9066251)
1. The pineal hormone melatonin in hematology and its potential efficacy in the treatment of thrombocytopenia.
Lissoni P; Tancini G; Barni S; Paolorossi F; Rossini F; Maffé P; Di Bella L
Recenti Prog Med; 1996 Dec; 87(12):582-5. PubMed ID: 9066251
[TBL] [Abstract][Full Text] [Related]
2. Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: a biological phase II study.
Lissoni P; Barni S; Brivio F; Rossini F; Fumagalli L; Tancini G
J Biol Regul Homeost Agents; 1995; 9(2):52-4. PubMed ID: 9127633
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
Lissoni P; Bolis S; Brivio F; Fumagalli L
Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
[TBL] [Abstract][Full Text] [Related]
4. Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic solid tumor patients: a phase II study.
Lissoni P; Malugani F; Brivio F; Piazza A; Vintimilla C; Giani L; Tancini G
Neuro Endocrinol Lett; 2003; 24(3-4):259-62. PubMed ID: 14523367
[TBL] [Abstract][Full Text] [Related]
5. Is there a role for melatonin in supportive care?
Lissoni P
Support Care Cancer; 2002 Mar; 10(2):110-6. PubMed ID: 11862501
[TBL] [Abstract][Full Text] [Related]
6. Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent.
Lissoni P
Pathol Biol (Paris); 2007; 55(3-4):198-200. PubMed ID: 17451889
[TBL] [Abstract][Full Text] [Related]
7. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
Lissoni P; Fumagalli L; Paolorossi F; Rovelli F; Roselli MG; Maestroni GJ
J Biol Regul Homeost Agents; 1997; 11(3):119-22. PubMed ID: 9498162
[TBL] [Abstract][Full Text] [Related]
8. Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: a study of interactions between tumor necrosis factor-alpha and the pineal hormone melatonin.
Lissoni P; Barni S; Tancini G; Brivio F; Tisi E; Zubelewicz B; Braczkowski R
J Biol Regul Homeost Agents; 1994; 8(4):126-9. PubMed ID: 7660855
[TBL] [Abstract][Full Text] [Related]
9. A biological study on the efficacy of low-dose subcutaneous interleukin-2 plus melatonin in the treatment of cancer-related thrombocytopenia.
Lissoni P; Barni S; Brivio F; Rossini F; Fumagalli L; Ardizzoia A; Tancini G
Oncology; 1995; 52(5):360-2. PubMed ID: 7637951
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
[TBL] [Abstract][Full Text] [Related]
11. Oncostatic activity of pineal neuroendocrine treatment with the pineal indoles melatonin and 5-methoxytryptamine in untreatable metastatic cancer patients progressing on melatonin alone.
Lissoni P; Rovelli F; Frassineti A; Fumagalli L; Malysheva O; Conti A; Maestroni G
Neuro Endocrinol Lett; 2000; 21(4):319-323. PubMed ID: 11455367
[TBL] [Abstract][Full Text] [Related]
12. Growth Factors: Thrombopoietic Property of the Pineal Hormone Melatonin.
Lissoni P; Mandala M; Rossini F; Fumagalli L; Barni S
Hematology; 1999; 4(4):335-343. PubMed ID: 11399574
[TBL] [Abstract][Full Text] [Related]
13. Preliminary study on modulation of the biological effects of tumor necrosis factor-alpha in advanced cancer patients by the pineal hormone melatonin.
Brackowski R; Zubelewicz B; Romanowski W; Lissoni P; Barni S; Tancini G; Maestroni GJ
J Biol Regul Homeost Agents; 1994; 8(3):77-80. PubMed ID: 7754792
[TBL] [Abstract][Full Text] [Related]
14. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms.
Lissoni P
Pathol Biol (Paris); 2007; 55(3-4):201-4. PubMed ID: 17446010
[TBL] [Abstract][Full Text] [Related]
15. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
Lissoni P; Malugani F; Malysheva O; Kozlov V; Laudon M; Conti A; Maestroni G
Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
[TBL] [Abstract][Full Text] [Related]
16. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors.
Lissoni P; Brivio F; Fumagalli L; Messina G; Vigoré L; Parolini D; Colciago M; Rovelli F
Anticancer Res; 2008; 28(2B):1377-81. PubMed ID: 18505083
[TBL] [Abstract][Full Text] [Related]
17. A study of light/dark rhythm of melatonin in relation to cortisol and prolactin secretion in schizophrenia.
Viganò D; Lissoni P; Rovelli F; Roselli MG; Malugani F; Gavazzeni C; Conti A; Maestroni G
Neuro Endocrinol Lett; 2001 Apr; 22(2):137-41. PubMed ID: 11335890
[TBL] [Abstract][Full Text] [Related]
18. Melatonin as a new possible anti-inflammatory agent.
Lissoni P; Rovelli F; Meregalli S; Fumagalli L; Musco F; Brivio F; Brivio O; Esposti G
J Biol Regul Homeost Agents; 1997; 11(4):157-9. PubMed ID: 9582617
[TBL] [Abstract][Full Text] [Related]
19. Neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin in AIDS patients with CD4 cell number below 200/mm3: a biological phase-II study.
Lissoni P; Vigorè L; Rescaldani R; Rovelli F; Brivio F; Giani L; Barni S; Tancini G; Ardizzoia A; Viganò MG
J Biol Regul Homeost Agents; 1995; 9(4):155-8. PubMed ID: 8844341
[TBL] [Abstract][Full Text] [Related]
20. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone.
Lissoni P; Cazzaniga M; Tancini G; Scardino E; Musci R; Barni S; Maffezzini M; Meroni T; Rocco F; Conti A; Maestroni G
Eur Urol; 1997; 31(2):178-81. PubMed ID: 9076462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
